10-Q: Precipio Inc. Reports Increased Revenue but Continues to Face Financial Challenges in Q3 2024

Precipio Inc. saw a revenue increase in Q3 2024, driven by higher diagnostic testing volumes, but ongoing losses and a working capital deficit raise concerns about its financial stability.

Summary

• Precipio Inc. reported a net loss of $3.9 million for the nine months ended September 30, 2024, and a net loss of $0.6 million for the three months ended September 30, 2024.
• The company's net sales increased to $13.1 million for the nine months ended September 30, 2024, and $5.2 million for the three months ended September 30, 2024, primarily due to a significant rise in diagnostic testing volumes.
• Diagnostic testing case volume increased by 78% for the nine months ended September 30, 2024, and 70% for the three months ended September 30, 2024, compared to the same periods in 2023.
• Product revenue decreased by $0.5 million for the nine months ended September 30, 2024, and $0.1 million for the three months ended September 30, 2024, compared to the same periods in 2023.
• The company's gross profit was $4.9 million for the nine months ended September 30, 2024, and $2.3 million for the three months ended September 30, 2024.
• Operating expenses decreased by $2.0 million to $8.8 million for the nine months ended September 30, 2024, and $0.5 million to $2.9 million for the three months ended September 30, 2024, compared to the same periods in 2023.
• As of September 30, 2024, Precipio had a working capital deficit of $1.2 million and an accumulated deficit of $102.1 million.
• The company has approximately $3.7 million available for future sales under its AGP 2023 Sales Agreement, including $1.0 million under the April 2024 Prospectus Supplement.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is revenue growth and cost reduction, the significant losses, working capital deficit, and going concern uncertainty create a negative sentiment. The company's dependence on future capital raises and the potential for dilution also contribute to the low score.

Positives

• The company experienced a significant increase in diagnostic testing case volume, indicating strong demand for its services.
• Net sales increased by 20% for the nine months ended September 30, 2024, and 15% for the three months ended September 30, 2024, demonstrating revenue growth.
• Operating expenses decreased by $2.0 million for the nine months ended September 30, 2024, and $0.5 million for the three months ended September 30, 2024, suggesting improved cost management.
• Gross profit increased due to higher case volumes and revenue, indicating potential for economies of scale.
• The company has access to additional capital through its AGP 2023 Sales Agreement.

Negatives

• Precipio continues to incur net losses, with a net loss of $3.9 million for the nine months ended September 30, 2024, and $0.6 million for the three months ended September 30, 2024.
• The company has a working capital deficit of $1.2 million as of September 30, 2024, indicating potential liquidity issues.
• Product revenue decreased by $0.5 million for the nine months ended September 30, 2024, and $0.1 million for the three months ended September 30, 2024, compared to the same periods in 2023.
• The company's accumulated deficit stands at $102.1 million, highlighting its history of losses.
• The company is dependent on raising additional financing to meet its debt obligations and pay liabilities.

Risks

• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• The company's ability to achieve or sustain profitability is uncertain and dependent on various factors, many of which are beyond its control.
• The company may need to raise substantial additional capital, and failure to do so could force delays or reductions in product development programs.
• The sale of common stock through the AGP 2023 Sales Agreement could cause significant dilution and a potential fall in the stock price.
• Cybersecurity risks could compromise the company's information and expose it to liability.
• The company's products could become subject to government regulations requiring marketing authorization, which may be expensive and time-consuming.
• Unfavorable U.S. or global economic conditions could adversely affect the company's business, financial condition, or results of operations.
• The company's operations and access to capital may be impacted by disruptions to the banking system and financial market volatility.

Future Outlook

The company's ability to continue as a going concern is dependent on achieving its business plan, generating additional revenue, and raising additional financing. There is substantial doubt about the company's ability to continue as a going concern over the next twelve months.

Management Comments

• Management believes that the company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.
• Management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

The healthcare industry is subject to numerous laws and regulations, including those related to licensure, accreditation, and government healthcare program participation. The company's performance is also affected by the competitive environment and related market conditions.

Comparison to Industry Standards

• The company's gross profit margin of 38% for the nine months ended September 30, 2024, and 44% for the three months ended September 30, 2024, is within the range of other diagnostic companies, but the company's net losses are a concern.
• The company's reliance on equity and debt financing is common in the biotechnology sector, but the company's working capital deficit and accumulated losses are significant.
• The company's increase in diagnostic testing case volume is a positive sign, but the decrease in product revenue is a concern.
• The company's operating expense reductions are a positive step, but the company needs to achieve profitability to ensure long-term sustainability.
• The company's stock option repricing is a common practice to retain employees, but the incremental compensation cost will impact the company's financials.

Legal Proceedings

• The company is involved in legal proceedings related to matters incidental to its business.
• The company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial challenges.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may experience disruptions in service due to the company's financial instability.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to achieve its business plan, including generating additional revenue.
• The company needs to raise additional financing to meet its debt obligations and pay liabilities.
• The company needs to address the potential impact of the FDA's final rule on LDTs.
• The company needs to continue to monitor and mitigate cybersecurity risks.

Key Dates

Keywords

cancer diagnostics, diagnostic testing, laboratory services, revenue growth, financial losses, working capital deficit, stock option repricing, cybersecurity risks, regulatory compliance, going concern